
A small study delivers startling results on the power of a new immunotherapy treatment against rectal cancer: The drug triggered remission in all the patients who got it. All of them had mismatch repair-deficient (MMRd) locally advanced rectal cancer and were given dostarlimab — an anti-PD-1 monoclonal antibody — every three weeks for six months… read on > read on >